Article Text

Download PDFPDF

Are autoantibodies against a 25-mer synthetic peptide of M3 muscarinic acetylcholine receptor a new diagnostic marker for Sjögren’s syndrome?
  1. P Žigon1,
  2. B Božič1,
  3. S Čučnik1,
  4. B Rozman1,
  5. M Tomšič1,
  6. T Kveder1
  1. 1University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
  1. Correspondence to:
    MsT Kveder
    University Medical Centre, Department of Rheumatology, Vodnikova 62, SI-1000 Ljubljana, Slovenia;
  1. T Sumida2
  1. 2Department of Internal Medicine, University of Tsukuba, Tsukuba City, Japan;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the article by Naito and colleagues,1 who recently proposed the autoantibodies against M3 muscarinic acetylcholine receptor (anti-M3R) as a new diagnostic marker for patients with Sjögren’s syndrome (SS).

We have been studying anti-M3R recently2 and reviewed some theoretical aspects.3 The results of our work with the same 25-mer synthetic peptide (K-R-T-V-P-P-G-E-C-F-I-Q-F-L-S-E-P-T-I-T-F-G-T-A-I) as used by Naito et al showed a similar prevalence of anti-M3 in patients with SS (table 1). Nevertheless, we did not draw the same conclusions and could not agree with the statement that antibodies against the 25-mer synthetic peptide might be a new diagnostic marker for SS.

Table 1

 Anti-M3R antibodies in patients with Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE), and healthy controls (C)

We believe that the authors should mention a misleading fact in the article by Bacman et al,4 which was discussed by Cavill et al and Dawson et al5,6—namely, the sequence of 25-mer synthetic peptide used by Bacman et al was in fact the amino acid sequence from the second extracellular loop of M4 muscarinic acetylcholine receptor. Neither of the two groups were able to detect the activity of anti-M3R with conventional immunological approaches. Furthermore, Gao et al constructed a CHO cell line expressing the human M3R gene and found positive anti-M3R antibodies in 9/11 patients with SS and in none of 11 healthy controls.7

The enzyme linked immunosorbent assay (ELISA) used by Naito et al was somewhat similar to our procedure. In our ELISA, Costar medium binding microtitre plates were coated with the same 25-mer peptide in absolute ethanol (10 mg/l), and incubated at 4°C for at least 3 hours. Serum samples were first diluted 1:100 in 1% bovine serum albumin (BSA)/phosphate buffered saline (PBS) (Naito et al 1:50 in 5% BSA/PBS) and incubated for 1 hour at room temperature (Naito et al for 2 hours at 37°C). Optical density values of anti-M3R were not normally distributed in any of our tested groups. Therefore, the cut off value was estimated at the 95th centile of 349 controls. Neither sensitivity nor specificity of the ELISA for SS was improved by binding the synthetic peptide to BSA by a cross linker (N-(γ-maleimidobutyryloxy)succinimide ester; Pierce).

In conclusion, it seems that the 25-mer synthetic peptide used in routine immunological techniques2,5,6 does not disclose clinically relevant antibodies, suggesting that a short linear peptide does not depict an adequate epitope for the binding of anti-M3R. Data presented by Gao et al, applying native M3R protein, seem far more promising, but they should be verified on a larger group of patients and controls.


Author’s reply

Dr Tanja Kveder et al point out two messages about our paper.1 Firstly, that our previous results1 are supported by their further experiments using the same 25-mer synthetic peptides. Secondly, they suggest that our statement that antibodies (Abs) to the 25-mer synthetic peptide might be a new diagnostic marker for SS is open to criticism.

We agree with Dr Kveder’s comments, in part, because we did not elucidate the function of the anti-25-mer synthetic peptide Abs using M3R transfected cells2 or HSG cell lines. However, Abs against the second extracellular portion of M3R are detected in a subgroup of patients with SS and the presence of this Ab is significantly associated with anti-SSB Ab.1 Therefore, we consider that anti-25-mer synthetic peptide Abs might be a new diagnostic marker in a subgroup of patients with SS. Of course, further experiments on the functional analysis using anti-25-mer synthetic peptide Abs and anti-M3R protein Abs would be helpful to clarify the better diagnostic marker in patients with SS.